A systematic review of prothrombin complex concentrate dosing strategies to reverse vitamin K antagonist therapy

N Khorsand, HAM Kooistra, RM van Hest… - Thrombosis research, 2015 - Elsevier
Management of patients with a major bleed while on vitamin K antagonist (VKA) is a
common clinical challenge. Prothrombin Complex Concentrates (PCC) provide a rapid …

[HTML][HTML] An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K …

N Khorsand, NJGM Veeger, RM van Hest… - …, 2012 - ncbi.nlm.nih.gov
Background Despite years of experience with vitamin K antagonist-associated bleeding
events, there is still no evidence to help identify the optimal treatment with prothrombin …

[HTML][HTML] Fixed versus variable dosing of prothrombin complex concentrate in vitamin K antagonist-related intracranial hemorrhage: a retrospective analysis

RA Abdoellakhan, IP Miah, N Khorsand, K Meijer… - Neurocritical care, 2017 - Springer
Background Millions of patients receive vitamin K antagonist (VKA) therapy worldwide.
Annually 0.2–1% of all VKA users develops an intracranial hemorrhage (ICH). Prothrombin …

Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy

N Khorsand, NJGM Veeger, M Muller… - Transfusion …, 2011 - Wiley Online Library
Background: Although prothrombin complex concentrate (PCC) is often used to counteract
vitamin K antagonist (VKA) therapy, evidence regarding the optimal dose for this indication …

[HTML][HTML] A meta‐analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor–related major bleeding

T Jaspers, K Shudofsky, MV Huisman, K Meijer… - Research and practice …, 2021 - Elsevier
Background Andexanet alfa (andexanet) and prothrombin complex concentrate (PCC) are
both reversal agents for major bleeding in patients using factor Xa inhibitors (FXaIs). Our aim …

[HTML][HTML] Fixed versus variable dosing of prothrombin complex concentrate for bleeding complications of vitamin K antagonists—the PROPER3 randomized clinical trial

RA Abdoellakhan, N Khorsand, E Ter Avest… - Annals of emergency …, 2022 - Elsevier
Study objective To determine if a fixed dose of 1000 IU of 4-factor prothrombin complex
concentrate (4F-PCC) is as effective as traditional variable dosing based on body weight …

Definition of haemostatic effectiveness in interventions used to treat major bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation

N Khorsand, J Beyer‐Westendorf… - … of Thrombosis and …, 2021 - Wiley Online Library
1 BACKGROUND A common challenge for studies investigating the hemostatic
effectiveness of the reversal agents or any other treatment used to manage a major bleed …

[HTML][HTML] A low fixed dose of prothrombin complex concentrate is cost effective in emergency reversal of vitamin K antagonists

N Khorsand, L Giepmans, K Meijer, RM van Hest… - …, 2013 - ncbi.nlm.nih.gov
** In model A a successful treatment is when a patient achieves both target INR and a
positive clinical outcome. In model B a successful treatment is when a patient has a positive …

Management of combined oral antithrombotic therapy by an antithrombotic stewardship program: A prospective study

ZX Zhang, J Schroeder‐Tanka… - British Journal of …, 2022 - Wiley Online Library
Aims Antithrombotic management initiatives could prevent inappropriate prescribing and
improve patient outcomes especially in patients on combined antithrombotic therapy. To …

Randomised controlled trial protocol to evaluate a fixed dose prothrombin complex concentrate against the variable dose in vitamin K antagonist related bleeding …

RA Abdoellakhan, N Khorsand, RM Van Hest… - BMJ open, 2018 - bmjopen.bmj.com
Introduction There is currently little evidence for the optimal dosing strategy of four-factor
prothrombin complex concentrates (PCC) in vitamin K antagonist (VKA)-related bleeds. The …